Preclinical development of novel dual pparand#945; and#947; agonists for the treatment of nafld and insulin resistance associated with type 2 diabetes

dc.contributor.guide	Manjula, S N
dc.coverage.spatial	Pharmacy
dc.creator.researcher	Guru, Bhavimani
dc.date.accessioned	2022-11-10T09:10:46Z
dc.date.available	2022-11-10T09:10:46Z
dc.date.awarded	2022
dc.date.completed	2022
dc.date.registered	2017
dc.description.abstract	available
dc.description.note	quotsummary p 70-71, References 72-85 p quot
dc.format.accompanyingmaterial	CD
dc.format.dimensions	3
dc.format.extent	i-xiii, 1-88 p
dc.identifier.uri	http://hdl.handle.net/10603/418079
dc.language	English
dc.publisher.institution	Colleges of Pharmacy
dc.publisher.place	Mysore
dc.publisher.university	JSS Academy of Higher Education and Research
dc.relation	227
dc.rights	university
dc.source.university	University
dc.subject.keyword	Clinical Pre Clinical and Health
dc.subject.keyword	Insulin resistance, NAFLD, Type 2 diabetes, PPARand#945;/and#947;, GLUT4, Akt, and AMPK
dc.subject.keyword	Pharmacology and Pharmacy
dc.subject.keyword	Pharmacology and Toxicology
dc.title	Preclinical development of novel dual pparand#945; and#947; agonists for the treatment of nafld and insulin resistance associated with type 2 diabetes
dc.title.alternative
dc.type.degree	Ph.D.